BackgroundThe typically poor outcomes of schizophrenia could be improved through
interventions that reduce cardiometabolic risk, negative symptoms and cognitive deficits; …

Aims 1) To determine the pooled prevalence of overweight and obesity in people with
severe mental illness (SMI), overall and by type of SMI, geographical region, and year of …

Objective Development of these guidelines is mandated by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and the American College of …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

BackgroundSevere mental illness (SMI) is thought to be associated with lower diet quality
and adverse eating behaviours contributing towards physical health disparities. A rigorous …

People with serious mental illness (SMI), including schizophrenia, bipolar disorder, and
major depressive disorder, have a higher mortality rate and shortened life expectancy. This …

The lifespan of people with severe mental illness (SMI) is shorter compared to the general
population. This excess mortality is mainly due to physical illness. We report prevalence …

Introduction Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses
generally are restricted to second generation antipsychotics (SGA) and do not stratify for …

Individuals with schizophrenia have high levels of medical comorbidity and cardiovascular
risk factors. The presence of 3 or more specific factors is indicative of metabolic syndrome …

Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as
obesity, hyperglycemia, dyslipidemia and the metabolic syndrome) that are associated with …